{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:46:07Z","timestamp":1781311567140,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.schres.2019.08.035","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:37:28Z","timestamp":1570556248000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review"],"prefix":"10.1016","volume":"225","author":[{"given":"Joanna","family":"Moncrieff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia E.","family":"Crellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2019.08.035_bb0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A\u00a0double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2019.08.035_bb0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1017\/S0033291706008579","article-title":"Remission and relapse in psychosis: operational definitions based on case-note data","author":"Bebbington","year":"2006","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2019.08.035_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/002076400004600308","article-title":"A\u00a0delphi approach to characterising \u201crelapse\u201d as used in UK clinical practice","volume":"46","author":"Burns","year":"2000","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0020","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1176\/ajp.144.11.1466","article-title":"A\u00a0comparative trial of pharmacologic strategies in schizophrenia","volume":"144","author":"Carpenter","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0025","first-page":"1138","article-title":"Continuous versus targeted medication in schizophrenic outpatients: outcome results","volume":"147","author":"Carpenter","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2019.08.035_bb0035","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaac.2017.06.013","article-title":"Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study","volume":"56","author":"Correll","year":"2017","journal-title":"J.\u00a0Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A\u00a0comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"NEJM"},{"key":"10.1016\/j.schres.2019.08.035_bb0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1988.tb05116.x","article-title":"Antipsychotic withdrawal symptoms: phenomenology and pathophysiology","volume":"77","author":"Dilsaver","year":"1988","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2019.08.035_bb0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cpr.2013.04.001","article-title":"Assessing early signs of relapse in psychosis: review and future directions","volume":"33","author":"Eisner","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.schres.2019.08.035_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1017\/S0033291700047899","article-title":"Relapse in schizophrenia: a review of the concept and its definitions","volume":"13","author":"Falloon","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2019.08.035_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0070","doi-asserted-by":"crossref","first-page":"pyw076","DOI":"10.1093\/ijnp\/pyw076","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2019.08.035_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2007.06.016","article-title":"Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia","author":"Gaebel","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","article-title":"Relapse prevention in first-episode schizophrenia\u2014maintenance vs intermittent drug treatment with prodrome-based early intervention","volume":"72","author":"Gaebel","year":"2011","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2010.02.1073","article-title":"A\u00a0systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis","volume":"119","author":"Gleeson","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0095","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two year relapse rates","author":"Hogarty","year":"1974","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0165-1781(79)90016-7","article-title":"Low dose fluphenazine decanoate treatment of schizophrenia in maintenance","volume":"348","author":"Kane","year":"1979","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A\u00a0randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2019.08.035_bb0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamapsychiatry.2019.0275","article-title":"Are placebo-controlled, relapse prevention trials in schizophrenia research still necessary or ethical?","volume":"76","author":"Lawrence","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0135","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2019.08.035_bb0140","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2019.08.035_bb0145","series-title":"Relapse Criteria Perspectives in Schizophrenic Disorders: Different Instruments","first-page":"273","author":"Linszen","year":"1994"},{"key":"10.1016\/j.schres.2019.08.035_bb0150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0447.1989.tb03032.x","article-title":"The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish schizophrenia research group","volume":"80","author":"McCreadie","year":"1989","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2019.08.035_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2019.08.035_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00432759","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics","volume":"77","author":"Nishikawa","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2019.08.035_bb0165","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-3223(89)90265-5","article-title":"Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride","volume":"25","author":"Nishikawa","year":"1989","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psychres.2004.04.018","article-title":"Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples","volume":"144","author":"Nuechterlein","year":"2006","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","author":"Olivares","year":"2013","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0022-3956(93)90059-B","article-title":"Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia","volume":"27","author":"Pietzcker","year":"1993","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.schres.2019.08.035_bb0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","article-title":"Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia","volume":"53","author":"Rui","year":"2014","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005053-199104000-00006","article-title":"Discontinuation of neuroleptic medication in older, outpatient schizophrenics: a placebo-controlled, double blind trial","volume":"179","author":"Ruskin","year":"1991","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2019.08.035_bb0195","article-title":"Intermittent drug techniques for schizophrenia","volume":"7","author":"Sampson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2019.08.035_bb0200","doi-asserted-by":"crossref","DOI":"10.3109\/13651501.2014.1002501","article-title":"Towards a pragmatic and operational definition of relapse in schizophrenia: a Delphi consensus approach","author":"San","year":"2015","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2019.08.035_bb0205","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/schbul\/12.3.394","article-title":"Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics","volume":"12","author":"Spohn","year":"1986","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.08.035_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A\u00a0double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.schres.2019.08.035_bb0215","doi-asserted-by":"crossref","unstructured":"Wang, C., Xiang, Y., Cai, Z.-J., Weng, Y., Qj, B., JP, Z., TQ, L., GH, W., SM, W., HY, Z., DF, C., WK, T., GS, U., Investigators., R.M.T. in S. (RMTS), 2010. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am. J. Psychiatry.","DOI":"10.1176\/appi.ajp.2009.09030358"},{"key":"10.1016\/j.schres.2019.08.035_bb0220","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40263-016-0345-4","article-title":"A\u00a0randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study","volume":"30","author":"Weiden","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2019.08.035_bb0225","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.08.035_bb0230","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:36:50Z","timestamp":1760297810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419303913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":46,"alternative-id":["S0920996419303913"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.035","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}